HWM
CYTK icon

Hemington Wealth Management’s Cytokinetics CYTK Stock Holding History

Hemington Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1K Hold
25
– – ﹤0.01% 1418
2025
Q2 		$0 Hold
25
– – ﹤0.01% 1551
2025
Q1 		$1K Sell
25
-8
-24% -$368 ﹤0.01% 1381
2024
Q4 		$1K Sell
33
-11
-25% -$571 ﹤0.01% 1381
2024
Q3 		$2K Buy
+44
New +$2.45K ﹤0.01% 1163

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Hemington Wealth Management's CYTK Position: Q3 2025 in Review

Hemington Wealth Management held its Cytokinetics (CYTK) position steady in Q3 2025 at 25 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

Hemington Wealth Management first reported a position in CYTK in Q3 2024 and has held it in 5 quarters since. The position peaked at $2K in Q3 2024. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • Hemington Wealth Management held 25 shares of Cytokinetics worth $1K as of Q3 2025.
  • Hemington Wealth Management left its Cytokinetics share count unchanged in Q3 2025.
  • Cytokinetics made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1418 holding.
  • Hemington Wealth Management first reported a position in Cytokinetics in Q3 2024 and has held it in 5 quarters since.
  • Hemington Wealth Management's Cytokinetics position peaked at $2K in Q3 2024.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.